Recruiting In Vitro Transcribed mRNA against Cancer Immunotherapy: A Contemporary Appraisal of the Current Landscape

• Published in: Current Issues in Molecular Biology Vol. 45; no. 11; pp. 9181 - 9214
• Main Authors: Miliotou, Androulla N, Georgiou-Siafis, Sofia K, Ntenti, Charikleia, Pappas, Ioannis S, Papadopoulou, Lefkothea C
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.11.2023
• Subjects: Antigens; Cancer; cancer immunotherapy; CAR T-cell therapy; Care and treatment; Chimeric Antigen Receptor (CAR); Health aspects; Immunotherapy; IVT-mRNA; IVT-mRNA cancer vaccines; Killer cells; Messenger RNA; personalized immunotherapy; Proteins; T cells; Vaccines; Massachusetts; Germany; CAR T-cell therapy; CAR NK-92 cells; PTD-IVT-mRNA; bioenergetics; cancer immunotherapy; Protein Transduction Domain; personalized immunotherapy; Chimeric Antigen Receptor (CAR); IVT-mRNA cancer vaccines; IVT-mRNA
• ISSN: 1467-3045; 1467-3037; 1467-3045
• DOI: 10.3390/cimb45110576

Over 100 innovative in vitro transcribed (IVT)-mRNAs are presently undergoing clinical trials, with a projected substantial impact on the pharmaceutical market in the near future. Τhe idea behind this is that after the successful cellular internalization of IVT-mRNAs, they are subsequently translated into proteins with therapeutic or prophylactic relevance. Simultaneously, cancer immunotherapy employs diverse strategies to mobilize the immune system in the battle against cancer. Therefore, in this review, the fundamental principles of IVT-mRNA to its recruitment in cancer immunotherapy, are discussed and analyzed. More specifically, this review paper focuses on the development of mRNA vaccines, the exploitation of neoantigens, as well as Chimeric Antigen Receptor (CAR) T-Cells, showcasing their clinical applications and the ongoing trials for the development of next-generation immunotherapeutics. Furthermore, this study investigates the synergistic potential of combining the CAR immunotherapy and the IVT-mRNAs by introducing our research group novel, patented delivery method that utilizes the Protein Transduction Domain (PTD) technology to transduce the IVT-mRNAs encoding the CAR of interest into the Natural Killer (NK)-92 cells, highlighting the potential for enhancing the CAR NK cell potency, efficiency, and bioenergetics. While IVT-mRNA technology brings exciting progress to cancer immunotherapy, several challenges and limitations must be acknowledged, such as safety, toxicity, and delivery issues. This comprehensive exploration of IVT-mRNA technology, in line with its applications in cancer therapeutics, offers valuable insights into the opportunities and challenges in the evolving landscape of cancer immunotherapy, setting the stage for future advancements in the field.